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Abstract
Objectives: This study investigated the impact of neoadjuvant radiation therapy (XRT) on postoperative
outcomes following pancreaticoduodenectomy for pancreatic cancer.
Methods: The American College of Surgeons National Quality Improvement Program database was
queried for the period 2005–2010 to assess complication rates following pancreaticoduodenectomy for
pancreatic cancer. Two groups of patients were identified, comprising those who received neoadjuvant
XRT and those who did not (control group).
Results: A total of 4416 patients were identified, including 200 in the XRT group and 4216 in the control
group. There were differences in patient characteristics between the groups, including in age, hyperten-
sion and bilirubin level. Despite the fact that weight loss was more common, median operative time was
longer (423 min versus 368 min; P < 0.001), and vascular reconstruction was more commonly required
(20.5% versus 8.4%; P < 0.001) in the XRT group. In addition, the XRT group had a shorter median
hospital stay than the control group (9 days versus 10 days; P = 0.005). Mortality (3.0% versus 2.7%;
P = 0.818) and morbidity (40.5% versus 37.6%; P = 0.404) rates were not influenced by neoadjuvant XRT.
Blood transfusion rates were increased in the XRT group (13.0% versus 7.4%; P = 0.003). Severe
complications were influenced by age >70 years, American Society of Anesthesiologists (ASA) class >2,
preoperative sepsis, dyspnoea, weight loss, impaired functional status, peripheral vascular disease and
operative time of >8 h.
Conclusions: Neoadjuvant XRT is not associated with an increase in complications after
pancreaticoduodenectomy.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death
in the USA.1 Surgical resection offers the only chance for cure.
However, even after potentially curable surgery, 5-year survival rates
remain dismal at <20%.2 To improve survival, various treatment
regimens and sequencing strategies incorporating chemotherapy
and radiation therapy (XRT) have been studied.3 As pancreatic
cancer has a propensity for early local spread via perineural sheaths
and lymphatic channels, there are anatomic and biological rationales
for using regional XRT to treat this infiltrative pattern of spread. In
support of this paradigm, chemoradiation therapy has been shown
to slow local progression and improve survival in locally advanced
pancreatic cancer.4 Recently, XRT has been increasingly utilized as
part of neoadjuvant therapy in patients with borderline resectable
pancreatic cancer. Its utility in the treatment of initially resectable
tumours is also being actively investigated.5–7
The influence of preoperative XRT on postoperative surgical
outcomes remains under debate. Radiation therapy induces
inflammatory changes in the pancreatic parenchyma and peripan-
creatic tissues, resulting in the gradual disruption of natural tissue
planes, which may make surgery more hazardous.8 Radiation
therapy combined with chemotherapy can also cause side-effects
such as gastrointestinal toxicity that may debilitate the patient in
the preoperative period, and these may increase surgical complica-
tion rates. However, there is some evidence that XRT may decrease
pancreatic fistula rates after pancreaticoduodenectomy.9,10 To the
present authors’knowledge, there has not been a close examination
of nationwide outcome data on the impact of preoperative XRT on
the safety of subsequent pancreaticoduodenectomy.
The primary aims of this study were to analyse the impact of
preoperative XRT on morbidity and mortality rates following
pancreaticoduodenectomy, and to identify predictors of severe
postoperative complications.
Materials and methods
The American College of Surgeons National Surgical Quality
Improvement Program (ACS-NSQIP) is a nationwide initiative
that generates prospective surgical outcome data for patients
treated at participating hospitals in the USA. Trained clinical
reviewers enter into a database information on patient demo-
graphics, medical comorbidities, preoperative laboratory values,
surgical details and perioperative events. A systemic audit process
has shown the accuracy and validity of the NSQIP data.11 Exami-
nation of this nationwide database allows for the risk stratification
of patients and meaningful comparisons of 30-day complication
rates among hospitals. Surgical outcomes available for study
include hospital length of stay (LoS), blood transfusion require-
ments during surgery and the 72-h postoperative period, and
details of complications including 30-day postoperative mortality.
As the present study institutions are participants in the ACS-
NSQIP, the current authors have access to and requested use of the
nationwide de-identified Participant User File (PUF).
The ACS-NSQIP database for 2005 to 2010 was queried to
identify patients with the diagnosis of pancreatic neoplasm
according to the International Classification of Diseases, 9th
Revision (ICD-9) codes 157 and 157.1, 157.2, 157.3, 157.4, 157.8
and 157.9. Patients with malignant neoplasm of islets of Lang-
erhans (ICD-9 code 157.4) were excluded. Next, using current
procedural terminology (CPT) codes, patients with pancreatic
cancer who underwent pylorus-preserving pancreaticoduo-
denectomy (CPT code 48153) or classic pancreaticoduodenec-
tomy (CPT code 48150) were identified. The study population
was then divided into two groups based on the use of XRT
before pancreaticoduodenectomy.
Patient characteristics such as age, gender, race, medical comor-
bidities, use of neoadjuvant chemotherapy, preoperative blood
transfusion, preoperative septic episodes, and laboratory test
results were compared. Perioperative variables were evaluated to
determine any differences between the two groups in terms of year
of operation, types of pancreaticoduodenectomy performed, need
for vascular reconstruction, operative time, intraoperative blood
transfusion requirement and hospital LoS. Surgical outcomes were
also determined to assess morbidity and mortality in each group.
Severe complications were defined as organ space infection, sepsis,
septic shock, reoperation, cardiac arrest and death; rates for each of
these were also compared between the XRT group and the control
group. Categorical variables were compared using the chi-squared
test and Fisher’s exact test as appropriate. Continuous variables
were compared using Student’s t-test or the Mann–Whitney U-test
as appropriate.
Univariate analysis was performed to identify preoperative or
perioperative variables that were associated with severe complica-
tions. Variables for which a P-value of < 0.1 was established on
univariate analysis were included in a multivariate logistic regres-
sion model to define independent predictors of severe postopera-
tive complications. Preoperative XRT was included in the logistic
regression analysis as it was the main study variable. P-values of
< 0.05 were considered to indicate statistical significance. Odds
ratios (ORs) and 95% confidence intervals (CIs) were also calcu-
lated. spss Version 15.0 (SPSS, Inc., Chicago, IL, USA) was used
for statistical analysis.
Results
A total of 9206 patients with the diagnosis of pancreatic cancer
were identified in the ACS-NSQIP PUF. Patients with malignant
neoplasms of the islet cells of Langerhans were excluded (n = 215).
A total of 4416 patients underwent either pylorus-preserving
(n = 1775) or classic (n = 2641) pancreaticoduodenectomy
for pancreatic cancer. These patients were divided into two
groups comprising, respectively, 200 (4.5%) patients who received
radiation treatment within the 90 days prior to surgery (XRT
group) and 4216 (95.5%) patients who did not (control group).
Table 1 reports details of patient demographics and medical
comorbidities. In comparison with the control group, patients in
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Table 1 Patient demographics and clinical characteristics
Variable Preoperative radiation therapy P-value
Yes (n = 200) No (n = 4216)
Age, years, median  SD 63  10.5 67  11.2 <0.001
Sex, n (%)
Female 108 (54.0%) 2024 (48.0%) 0.226
Male 92 (46.0%) 2186 (51.9%)
BMI, kg/m2, median  SD 25.5  5.2 25.8  5.5 0.037
Weight loss, n (%) 66 (33.0%) 975 (23.1%) 0.001
Preoperative chemotherapy, n (%) 57 (28.5%) 69 (1.6%) <0.001
Hypertension, n (%) 89 (44.5%) 2353 (55.8%) 0.002
Diabetes, n (%) 53 (26.5%) 1095 (26.0%) 0.868
Dyspnoea, n (%)
At rest 1 (0.5%) 19 (0.5%) 0.89
Moderate exertion 14 (7.0%) 334 (7.9%)
No 185 (92.5%) 3863 (91.6%)
Functional status, n (%)
Normal 197 (98.5%) 4079 (96.8%) 0.172
Impaired 3 (1.5%) 136 (3.2%)
COPD, n (%) 9 (4.5%) 184 (4.4%) 0.927
Pneumonia, n (%) 0 8 (0.2%) 0.537
Preoperative sepsis, n (%) 4 (2.0%) 114 (2.7%) 0.538
Ascites, n (%) 2 (1.0%) 32 (0.8%) 0.703
Congestive heart failure, n (%) 0 18 (0.4%) 0.354
Myocardial infarction, n (%) 2 (1.0%) 11 (0.3%) 0.059
Percutaneous coronary intervention, n (%) 18 (9.0%) 291 (6.9%) 0.256
Previous cardiac surgery, n (%) 6 (3.0%) 253 (6.0%) 0.78
History of angina, n (%) 0 17 (0.4%) 0.368
Peripheral vascular disease, n (%) 1 (0.5%) 66 (1.6%) 0.228
Dialysis, n (%) 0 12 (0.3%) 0.45
Stroke, n (%) 0 56 (1.3%) 0.101
Steroid, n (%) 4 (2.0%) 80 (1.9%) 0.917
Emergency, n (%) 2 (1.0%) 34 (0.8%) 0.766
ASA class, n (%)
1 1 (0.5%) 42 (1.0%) 0.975
2 57 (28.5%) 1151 (27.3%)
3 131 (65.5%) 2769 (65.7%)
4 11 (5.5%) 250 (5.9%)
Unknown 0 4 (9.5%)
Smoking, n (%) 51 (25.5%) 872 (20.7%) 0.102
Alcohol, n (%) 4 (2.0%) 125 (3.0%) 0.429
Serum sodium, mmol/l, median  SD 139  3 139  3.2 0.264
BUN, mg/dl, median  SD 12  4.8 14  7.5 <0.001
Creatinine, mg/dl, median  SD 0.8  0.2 0.9  0.4 <0.001
Albumin, g/dl, median  SD 3.8  0.6 3.7  0.7 0.243
Bilirubin, mg/dl, median  SD 0.6  0.9 1.2  3.5 <0.001
SGOT, IU/l, median  SD 33  34 37  84 0.034
Alkaline phosphatase IU/l, median  SD 123  147 154  193 0.017
White blood cell count, 109/l, median  SD 5.6  2.5 7.2  2.8 <0.001
Haematocrit, %, median  SD 36.6  4.2 37.5  5.0 0.136
Platelets, 109/l, median  SD 230  100 264  101 <0.001
International normalized ratio, median  SD 1.1  0.5 1.1  0.2 0.407
SD, standard deviation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ASA, American Society of Anesthesiologists; BUN, blood urea nitrogen, SGOT, serum
glutamic oxaloacetic transaminase.
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the XRT group were younger (median age: 63 years versus 67
years; P < 0.001) and less likely to have hypertension (44.5%
versus 55.8%; P = 0.002). Patients in the XRT group also had
higher rates of preoperative weight loss (33.0% versus 23.1%; P =
0.001) and a lower body mass index (BMI) (median: 25.5 kg/m2
versus 25.8 kg/m2; P = 0.037). In addition, preoperative chemo-
therapy within 30 days of surgery was given more frequently in the
XRT group (28.5% versus 1.6%; P < 0.001). In terms of preopera-
tive laboratory values, patients in the XRT group had lower
median bilirubin (0.6 mg/dl versus 1.2 mg/dl; P < 0.001), serum
glutamic oxaloacetic transaminase (SGOT) (33 IU/l versus
37 IU/l; P = 0.034) and alkaline phosphatase (123 IU/l versus
154 IU/l; P = 0.017). In addition, median blood urea nitrogen
(BUN) (12 mg/dl versus 14 mg/dl; P < 0.001), creatinine
(0.8 mg/dl versus 0.9 mg/dl; P < 0.001), white blood cell counts
(5.6 ¥ 109/l versus 7.2 ¥ 109/l; P < 0.001) and platelet counts
(230 ¥ 109/l versus 264 ¥ 109/l; P < 0.001) were lower in the XRT
group than in the control group.
Table 2 depicts perioperative details. The neoadjuvant use of
XRT was found to have increased over the 5-year study period
(P < 0.001). In 2010, neoadjuvant XRT was given to 7.5% of
patients prior to pancreaticoduodenectomy performed for pan-
creatic cancer at NSQIP participating hospitals, reflecting an
increase from 2.7% in 2006. Intraoperative blood transfusion
rates were similar in the XRT group and the control group
(P = 0.507). However, in the XRT group, surgery times were longer
(median operative time: 423 min versus 368 min; P < 0.001), vas-
cular reconstruction was required more frequently (20.0% versus
8.3%; P < 0.001), and classic pancreaticoduodenectomy was more
commonly performed (74.0% versus 59.1%; P < 0.001). Despite
the apparent increase in operative magnitude, hospital LoS was
shorter in the XRT group (median LoS: 9 days versus 10 days;
P = 0.005).
Table 3 details the comparison of surgical outcomes between
the two groups. Mortality rates were 3.0% and 2.7% in the XRT
group and control group, respectively (P = 0.818). Overall mor-
bidity rates were not influenced by preoperative XRT (40.5%
Table 2 Perioperative details
XRT group Control group P-value
Operative year, n (%)
2005 8 (5.3%) 142 (94.7%) <0.001
2006 13 (2.7%) 469 (97.3%)
2007 28 (3.3%) 813 (96.7%)
2008 32 (3.5%) 875 (96.5%)
2009 39 (4.0%) 937 (96.0%)
2010 80 (7.5%) 980 (92.5%)
Type of pancreaticoduodenectomy, n (%)
Classic (CPT 48150) 148 (74.0%) 2493 (59.1%) <0.001
Pylorus-preserving (CPT 48153) 52 (26.0%) 1723 (40.9%)
Vascular reconstruction, n (%) 40 (20.0%) 350 (8.3%) <0.001
Intraoperative blood transfusion, n (%) 50 (25.0%) 1144 (27.1%) 0.507
Operative time, min, median  SD 423  134 368  128 <0.001
Length of hospital stay, days, median  SD 9  9 10  11 0.005
CPT, current procedural terminology; SD, standard deviation.
Table 3 Postoperative complications
Complication Preoperative radiation P-value
Yes, n (%) No, n (%)
Mortality 6 (3.0%) 115 (2.7%) 0.818
Overall morbidity 81 (40.5%) 1584 (37.6%) 0.404
Severe complications 38 (19.0%) 903 (21.4%) 0.414
Superficial incisional infection 25 (12.5%) 413 (9.8%) 0.211
Deep incisional infection 2 (1.0%) 99 (2.3%) 0.213
Organ space infection 13 (6.5%) 369 (8.8%) 0.268
Wound dehiscence 4 (2.0%) 85 (2.0%) 0.987
Pneumonia 6 (3.0%) 209 (5.0%) 0.209
Re-intubation 8 (4.0%) 222 (5.3%) 0.431
Pulmonary embolism 3 (1.5%) 38 (0.9%) 0.388
Deep vein thrombosis 5 (2.5%) 90 (2.1%) 0.728
Failure to wean ventilation 6 (3.0%) 245 (5.8%) 0.093
Acute renal insufficiency 1 (0.5%) 28 (0.7%) 0.779
Acute renal failure 1 (0.5%) 51 (1.2%) 0.363
Urinary tract infection 12 (6.0%) 197 (4.7%) 0.388
Stroke 0 18 (0.4%) 0.354
Cardiac arrest 1 (0.5%) 54 (1.3%) 0.331
Myocardial infarction 2 (1.0%) 28 (0.7%) 0.572
Postoperative blood transfusion 26 (13.0%) 310 (7.4%) 0.003
Sepsis 16 (8.0%) 418 (9.9%) 0.374
Septic shock 11 (5.5%) 177 (4.2%) 0.373
Reoperation 9 (4.5%) 308 (7.3%) 0.133
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versus 37.6%; P = 0.404). Severe complications occurred at similar
rates in both groups (19.0% versus 21.4%; P = 0.414). In terms of
specific complications, the only difference between the study
groups concerned the rate of postoperative blood transfusion,
which was required more frequently in the XRT group than in the
control group (13.0% versus 7.4%; P = 0.003). In addition, in
order to compare the impact of age differences between the two
groups on rates of severe complications, groups were stratified
by age (<50 years, 50–70 years, >70 years) for further analysis
(Table 4). Preoperative XRT did not influence rates of severe com-
plications in any of the age groups (P = NS). In order to compen-
sate for the lack of staging information in the NSQIP database,
patients were grouped according to need for vascular reconstruc-
tion as a surrogate marker for vascular involvement by the tumour
(Table 4). In patients who required vascular reconstruction, rates
of severe complications were not influenced by preoperative XRT
(35.0% versus 23.7%; P = 0.118). However, interestingly, in
patients who did not require vascular reconstruction, a trend
towards lower rates of severe complications emerged in those who
received preoperative XRT compared with those who did not
(15.0% versus 21.2%; P = 0.059).
Univariate analysis showed 13 variables associated with severe
complications (P < 0.10) (Table 5). On multivariate logistic
regression analysis, older age, American Society of Anesthesiolo-
gists (ASA) class of >2, preoperative weight loss, dyspnoea, preop-
erative sepsis, impaired functional status, history of peripheral
vascular disease and a surgery time of >8 h emerged as independ-
ently associated with severe complications. Preoperative XRT was
not found to be a significant predictor in either univariate or
logistic regression analysis.
Discussion
This contemporary, multi-institution analysis of ACS-NSQIP
data demonstrates that, although still uncommon, the use of
neoadjuvant XRT in pancreatic cancer has increased steadily in
recent years. Because pancreatic cancer is associated with early
local and distant recurrences, even after potentially curative
surgery, preoperative treatment with XRT in combination with
chemotherapy has several theoretical advantages.3 The neoadju-
vant phase of the multimodal treatment allows early treatment of
systemic micro-metastases and selection of those with favourable
tumour biology and good performance status who would benefit
the most from pancreaticoduodenectomy.12 In support of this
claim, Evans et al. reported that patients with resectable pancreatic
cancer can achieve median survival of 34 months and 5-year sur-
vival of 36% with a clinical protocol consisting of neoadjuvant
treatment with gemcitabine and 30-Gy XRT followed by pancrea-
ticoduodenectomy.7 The benefits of neoadjuvant therapy,
however, may be overshadowed by potential systemic and local
effects of irradiation that impact outcomes in the postoperative
period. To address these issues, this study explored the relation-
ship between neoadjuvant XRT and surgical complications.
The analysis indicated that morbidity and mortality rates in
patients who had received neoadjuvant XRT were similar to those
in patients who proceeded directly to surgery. Even when patients
were stratified by age or need for vascular reconstruction, rates of
severe complications were not affected by neoadjuvant XRT. This
finding is supported by the literature.13,14 Spitz et al.,15 for
example, found a complication rate of 24% in 41 patients who
underwent surgery after chemoradiation treatment, in compari-
son with 21% in 19 patients who proceeded directly to surgery.
However, the present study is unique in that it used a validated
national database to specifically investigate the impact of neoad-
juvant XRT on postoperative complications. The fact that vascular
reconstruction was required more frequently suggests that bor-
derline resectable tumours were more common in the XRT group.
In addition, operative times were longer and postoperative blood
transfusion was given more frequently in the XRT group. Despite
the presence of these factors, which typically would increase the
Table 4 Severe complications stratified by age group and need for vascular reconstruction in patients who did and did not undergo
preoperative radiation therapy (XRT)
Age group Preoperative XRT Severe complications P-value
No, n (%) Yes, n (%)
<50 years Yes 16 (76.2%) 5 (23.8%) 0.643
No 278 (80.3%) 68 (19.7%)
50–70 years Yes 105 (82.7%) 22 (17.3%) 0.635
No 1733 (81.0%) 407 (19.0%)
>70 years Yes 41 (78.8%) 11 (21.2%) 0.554
No 1302 (75.3%) 428 (24.7%)
Vascular reconstruction Preoperative XRT Severe complications P-value
No, n (%) Yes, n (%)
Yes Yes 26 (65.0%) 14 (35.0%) 0.118
No 267 (76.3%) 83 (23.7%)
No Yes 136 (85.0%) 24 (15.0%) 0.059
No 3046 (78.8%) 820 (21.2%)
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expected complication rates, the rates observed were similar to
those in non-irradiated patients, and hospital stay was shorter in
the XRT group. The present observation that postoperative blood
transfusion rates were increased in the XRT group raises concerns
over a potential deleterious impact on tumour recurrence and
longterm survival.16 However, the present study shows that safety
of surgery is not compromised by neoadjuvant XRT.
On multivariate logistic regression analysis, neoadjuvant XRT
did not influence rates of severe complications; rather, factors
such as greater age, impaired functional status, preoperative
sepsis, dyspnoea, weight loss, peripheral vascular disease, an ASA
class of >2 and a long operative time were independently associ-
ated with the development of severe complications. Although
association does not prove causation, an attempt to remedy these
issues during and after XRT may improve surgical outcomes.
Given the favourable outcomes observed in the XRT group,
despite the technically more demanding operations performed in
this group, it appears that the preoperative period benefits these
patients. Further studies will be needed to determine the optimal
recovery period between chemoradiation therapy and surgery to
achieve the proper balance between tumour response, patient pre-
habilitation, and the onset of radiation-induced inflammatory
changes.
A common major morbidity specific to pancreatic surgery is
pancreatic leak. Several studies have suggested that XRT may
reduce pancreatic leak by impairing pancreatic exocrine function
Table 5 Univariate and logistic regression analysis of predictors of severe complications
Variables Univariate analysis Logistic regression analysis Odds ratio 95% CI
P-value P-value
Sex 0.018 0.875
Age >70 years 0.001 <0.001 1.32 1.14–1.54
Body mass index >35 0.805
Coronary artery disease 0.342
Congestive heart failure 0.520
Hypertension 0.755
Diabetes 0.889
COPD 0.125
Preoperative presence of ascites 0.202
Peripheral vascular disease 0.003 0.002 2.19 1.32–3.64
Transient ischaemic attack/stroke 0.621
Smoking 0.992
Preoperative dyspnoea 0.008 0.002 1.47 1.15–1.88
Impaired functional status before surgery 0.005 0.005 1.72 1.18–2.51
Steroid use 0.253
Preoperative weight loss 0.004 0.003 1.31 1.09–1.57
Preoperative blood transfusion 0.510
Preoperative chemotherapy 0.968
Preoperative radiation therapy 0.617 0.772
Preoperative sepsis <0.001 <0.001 2.62 1.77–3.87
ASA class >2 0.058 0.025 1.22 1.03–1.46
Operative time >8 h <0.001 <0.001 1.43 1.20–1.71
Vascular reconstruction 0.174
Sodium <135 0.070 0.072
Creatinine >1.4 0.866
Albumin <3 0.032 0.051
Bilirubin >1.0 0.192
White blood cell count >11 0.277
Haematocrit <30 0.091 0.222
Platelet <150 0.142
International normalized ratio >1.5 0.019 0.171
95% CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; ASA, American Society of Anesthesiologists.
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and also by inducing fibrosis of the pancreatic gland, making it
more amenable to suture placement.9,10 The standard ACS-NSQIP
dataset does not document pancreatic leak as a separate outcome
measure. However, potential surrogates for clinically relevant pan-
creatic leak, such as deep organ space surgical site infection, sepsis,
septic shock, reoperation, cardiac arrest and death were available
for analysis. The rates of these severe complications were similar
between the two study groups. Data from the hepatopancreato-
biliary (HPB)-specific NSQIP demonstration project introduced
in 2011 suggests that deep organ space infection is only 55%
sensitive for pancreatic fistula in the NSQIP database, which
potentially explains these results (H. Pitt, personal communica-
tion, 2012). Further analysis from the HPB-NSQIP Collaborative
may contribute towards the specific examination of the role of
neoadjuvant XRT in pancreatic leak rates.
The present study adds to a growing body of surgical literature
derived from national databases with third-party reporting of
outcomes, which is unlike previously reported case series studies
from specialist single institutions. There are, however, limitations
to the current study that warrant mention. For instance, the dif-
ferences in demographic findings between the two groups, such as
in age, preoperative weight loss and BMI, may have affected sur-
gical outcomes. Furthermore, the fact that preoperative use of
chemotherapy is captured in the database only if it occurs within
30 days of surgery may have influenced the documented fre-
quency of preoperative chemotherapy in this study. Most impor-
tantly, the lack of data on hospital setting and surgeon experience
in the NSQIP database may have confounded the current findings
because more difficult surgeries associated with locally advanced
disease are more likely to have been performed at tertiary centres
with specialized surgical expertise and multidisciplinary support.
Conclusions
Clearly, the decision on whether to treat a patient with pancreatic
cancer with neoadjuvant chemoradiation therapy is complex. The
main finding of this study, that the use of neoadjuvant XRT is not
associated with increased complications after pancreaticoduo-
denectomy, is an important piece of information to be used in
determining the optimal treatment strategy for patients with
newly diagnosed pancreatic cancer. Further studies are needed to
determine the appropriate role of neoadjuvant XRT, including
patient selection, optimal dose, and sequencing with chemo-
therapy and surgery, in order to maximize its benefits.
Conflicts of interest
None declared.
References
1. Siegel R, Ward E, Brawley O, Jemal A. (2011) Cancer statistics, 2011: the
impact of eliminating socioeconomic and racial disparities on premature
cancer deaths. CA Cancer J Clin 61:212–236.
2. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC,
Coleman J et al. (2006) 1423 pancreaticoduodenectomies for pancreatic
cancer: a single-institution experience. J Gastrointest Surg 10:1199–
1210.
3. Ko AH, Crane CH. (2010) Radiation therapy in operable and
locally advanced pancreatic cancer. J Natl Compr Canc Netw 8:1022–
1031.
4. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D et al.
(2011) Gemcitabine alone versus gemcitabine plus radiotherapy in
patients with locally advanced pancreatic cancer: an Eastern Coopera-
tive Oncology Group trial. J Clin Oncol 29:4105–4112.
5. National Comprehensive Cancer Network. NCCN Clinical Practice
Guidelines in Oncology. Pancreatic Adenocarcinoma Version 2. 2012.
Fort Washington, PA: NCCN.
6. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C,
Goswitz MS et al. (1998) Rapid-fractionation preoperative chemoradia-
tion, pancreaticoduodenectomy, and intraoperative radiation therapy
for resectable pancreatic adenocarcinoma. J Clin Oncol 16:3843–
3850.
7. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW
et al. (2008) Preoperative gemcitabine-based chemoradiation for patients
with resectable adenocarcinoma of the pancreatic head. J Clin Oncol
26:3496–3502.
8. Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol
NJ et al. (2003) Neoadjuvant chemoradiotherapy for adenocarcinoma of
the pancreas: analysis of histopathology and outcome. Int J Gastrointest
Cancer 34:121–128.
9. Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P
et al. (1997) Prospective, randomized trial of octreotide to prevent pan-
creatic fistula after pancreaticoduodenectomy for malignant disease. Ann
Surg 226:632–641.
10. Ishikawa O, Ohigashi H, Imaoka S, Teshima T, Inoue T, Sasaki Y et al.
(1991) Concomitant benefit of preoperative irradiation in preventing pan-
creas fistula formation after pancreatoduodenectomy. Arch Surg
126:885–889.
11. Shiloach M, Frencher SK Jr, Steeger JE, Rowell KS, Bartzokis K, Tomeh
MG et al. (2010) Toward robust information: data quality and inter-rater
reliability in the American College of Surgeons National Surgical Quality
Improvement Program. J Am Coll Surg 210:6–16.
12. Goodman KA, Hajj C. (2013) Role of radiation therapy in the management
of pancreatic cancer. J Surg Oncol 107:86–96.
13. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A
et al. (2006) Pancreatic resections after chemoradiotherapy for locally
advanced ductal adenocarcinoma: analysis of perioperative outcome
and survival. Ann Surg Oncol 13:1201–1208.
14. Delanian S, Lefaix JL. (2007) Current management for late normal tissue
injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol
17:99–107.
15. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ
et al. (1997) Preoperative and postoperative chemoradiation strategies in
patients treated with pancreaticoduodenectomy for adenocarcinoma of
the pancreas. J Clin Oncol 15:928–937.
16. Kneuertz PJ, Patel SH, Chu CK, Maithel SK, Sarmiento JM, Delman KA
et al. (2011) Effects of perioperative red blood cell transfusion on disease
recurrence and survival after pancreaticoduodenectomy for ductal
adenocarcinoma. Ann Surg Oncol 18:1327–1334.
356 HPB
HPB 2014, 16, 350–356 © 2013 International Hepato-Pancreato-Biliary Association
